Mirion Technologies
MIR
$17.46
-5.37%
Mirion Technologies, Inc. is a specialized industrial company that provides products, services, and software for the safe and effective use of ionizing radiation across critical applications. It operates through two primary segments: Nuclear & Safety, which serves the nuclear energy, defense, and laboratory markets, and Medical, which focuses on improving cancer care delivery and medical diagnostics. The current investor narrative centers on the company's execution within a renewed growth phase, as evidenced by a return to profitability and significant revenue growth in its latest quarter, though this is juxtaposed against a challenging stock price performance that has lagged the broader market, raising questions about market sentiment and valuation.…
MIR
Mirion Technologies
$17.46
MIR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mirion Technologies's 12-month outlook, with a consensus price target around $22.70 and implied upside of +30.0% versus the current price.
Average Target
$22.70
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$14 - $23
Analyst target range
Analyst coverage for Mirion is limited, with only 3 analysts providing estimates, which is typical for a mid-cap company and can lead to higher volatility and less efficient price discovery. The consensus estimates point to significant earnings growth, with an average EPS forecast of $0.81 for the coming period, representing a dramatic increase from the $0.07 reported in Q4 2025, and average revenue estimates of $1.31 billion. The institutional ratings data shows a consistently bullish stance among covering firms, with recent actions from Baird (Outperform), JP Morgan (Overweight), Goldman Sachs (Buy), and Citigroup (Buy) all maintaining positive ratings, indicating underlying fundamental conviction despite the stock's weak price action. The lack of a published average price target and range in the data necessitates a focus on the qualitative analyst sentiment, which appears supportive, though the limited number of analysts underscores the stock's profile as one with higher uncertainty and potentially greater opportunity for re-rating as the investment story evolves.
Bulls vs Bears: MIR Investment Factors
The bull case for MIR is fundamentally driven by a clear operational turnaround, marked by a return to profitability, accelerating revenue growth, and strong analyst conviction in its forward earnings potential. The bear case is dominated by valuation concerns, severe technical damage, and skepticism reflected in high short interest. Currently, the bearish technical and valuation evidence appears stronger, as the stock's 22% six-month decline and 180x trailing P/E overshadow the improving fundamentals. The single most important tension in the investment debate is whether the company can deliver on the massive earnings growth (from $0.07 to $0.81 EPS) embedded in its forward 28x P/E multiple to validate its premium sales multiple, or if the current price action foreshadows a failure to meet these heightened expectations.
Bullish
- Return to Profitability & Accelerating Growth: The company posted a significant Q4 net income of $17.3M, a sharp reversal from a $13.6M loss in Q3 2024. Revenue grew 9.1% YoY in Q4 to $277.4M, indicating a renewed growth phase after previous quarters of declines or minimal growth.
- Strong Analyst Conviction: Despite limited coverage, all 3 analysts maintain bullish ratings (Outperform/Overweight/Buy), signaling institutional confidence in the fundamental story. Their average EPS estimate for the coming period is $0.81, implying a dramatic 1057% increase from the Q4 reported EPS of $0.07.
- Robust Balance Sheet & Cash Flow: The company has a strong liquidity position with a current ratio of 2.84 and a manageable debt-to-equity ratio of 0.66. Trailing twelve-month free cash flow is a healthy $107.4M, providing internal resources to fund growth and operations.
- Gross Margin Expansion: Gross margin expanded to 48.8% in Q4 2025 from 46.8% in Q3 2025, demonstrating improving operational efficiency and potential pricing power. This trend supports the thesis of a strengthening business model as revenue scales.
Bearish
- Extreme Valuation on Trailing Earnings: The trailing P/E ratio is an astronomical 180.2x, reflecting the market's capitalization of very modest earnings. While the forward P/E of 28.2x is more reasonable, it still requires flawless execution of projected EPS growth to justify.
- Persistent Price Downtrend & Weakness: The stock has underperformed the market severely, with a 1-year relative strength of -33.45% versus the S&P 500. It is down 14.3% over the past year and has a maximum drawdown of -46.8%, indicating sustained selling pressure and negative momentum.
- Thin Profitability & High Sales Multiple: Annualized profitability remains low, with a net margin of 3.1% and an operating margin of 5.6%. Despite this, the stock trades at a Price-to-Sales ratio of 5.82x, a premium valuation that demands sustained high growth to be justified.
- Limited Analyst Coverage & Visibility: Only 3 analysts provide estimates, which can lead to higher volatility and less efficient price discovery. The lack of a published average price target range in the data adds uncertainty for investors trying to gauge fair value.
MIR Technical Analysis
The prevailing price trend for Mirion Technologies is a pronounced downtrend, with the stock down 22.32% over the last six months and 14.31% over the past year. The current price of $18.45 sits near the lower end of its 52-week range, positioned at approximately 31% of the span between its 52-week low of $15.58 and high of $30.28, indicating the stock is deeply oversold and potentially presenting a value opportunity, albeit with significant technical damage. Recent momentum shows a modest short-term recovery, with the stock up 8.79% over the past month, which diverges positively from the longer-term downtrend and could signal a potential bottoming process or a relief rally from deeply oversold conditions. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $30.28 and firm support at the 52-week low of $15.58; a sustained breakdown below $15.58 would signal a continuation of the bearish trend, while a move above recent consolidation highs near $20 could indicate a more durable recovery. The stock's beta of 1.03 suggests its volatility is nearly identical to the broader market, yet its severe underperformance, with a relative strength of -33.45% over one year, highlights significant idiosyncratic risk and negative sentiment.
Beta
1.03
1.03x market volatility
Max Drawdown
-46.8%
Largest decline past year
52-Week Range
$16-$30
Price range past year
Annual Return
-19.6%
Cumulative gain past year
| Period | MIR Return | S&P 500 |
|---|---|---|
| 1m | -4.5% | -2.0% |
| 3m | -6.1% | +13.9% |
| 6m | -25.4% | +8.7% |
| 1y | -19.6% | +20.5% |
| ytd | -26.7% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MIR Fundamental Analysis
Mirion's revenue trajectory shows a return to solid growth, with Q4 2025 revenue of $277.4 million representing a 9.1% year-over-year increase, a significant acceleration from the revenue declines and minimal growth seen in prior quarters of 2025. The company's Product segment, at $166.1 million for the period, is the primary growth driver, substantially larger than the $57.0 million Service segment, indicating strength in its core equipment and technology sales. The company has returned to profitability, posting net income of $17.3 million in Q4 2025, a sharp improvement from a net loss of $13.6 million in Q3 2024, while gross margin expanded to 48.8% in the latest quarter from 46.8% in Q3 2025, demonstrating improved operational efficiency and pricing power. Profitability metrics, however, remain thin on an annualized basis, with a trailing net margin of 3.1% and an operating margin of 5.6%, indicating the business is still in the early stages of translating top-line growth into substantial bottom-line results. The balance sheet and cash flow position appear healthy, with a strong current ratio of 2.84, a manageable debt-to-equity ratio of 0.66, and positive free cash flow of $107.4 million on a trailing twelve-month basis, providing ample liquidity to fund operations and growth internally without excessive reliance on external financing.
Quarterly Revenue
$277400000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.48%
Latest Quarter
Free Cash Flow
$107400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MIR Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is an extremely high 180.2x, which reflects the market capitalizing very modest earnings, while the forward PE of 28.2x, based on analyst EPS estimates, indicates the market is pricing in a significant expansion of profitability in the coming year. Compared to sector averages, Mirion trades at a substantial premium on a sales basis, with a Price-to-Sales ratio of 5.82x, though direct industry average comparisons are not available in the provided data; the high PS ratio suggests the market is valuing its growth profile and niche market position ahead of current profitability. Historically, the stock's current trailing PE of 180.2x is near the peak of its own range over the past several quarters, which have seen wide swings from negative values to over 450x, indicating the current valuation embeds high expectations for sustained earnings improvement after a volatile profitability history.
PE
180.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -46x~2727x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Mirion's primary financial risk stems from its valuation, which is disconnected from current profitability. A trailing P/E of 180x and a forward P/E of 28x, coupled with thin net margins of 3.1%, create significant downside risk if the anticipated earnings growth fails to materialize. While the balance sheet is healthy with a 0.66 debt-to-equity ratio, the company's revenue concentration in its Product segment ($166.1M in Q4 vs. $57.0M for Services) could pose a risk if demand in its core nuclear, safety, or medical equipment markets slows. The recent return to profitability is promising but nascent, and earnings volatility remains a concern given the net loss reported just two quarters prior.
Market & Competitive Risks: The stock trades at a substantial premium on a sales basis (P/S of 5.82x), making it vulnerable to valuation compression, especially in a higher interest rate environment that pressures growth stock multiples. Its beta of 1.03 suggests it moves with the market, yet its -33.45% relative strength over one year indicates severe idiosyncratic underperformance, highlighting negative sentiment specific to the story. Competitive risks are inherent in its specialized industrial and medical markets, where technological disruption or pricing pressure could threaten margins that have only recently begun to expand from 46.8% to 48.8%.
Worst-Case Scenario: The worst-case scenario involves a failure to achieve the analyst-projected $0.81 EPS, coupled with a re-rating of the stock from its forward 28x P/E to a more distressed multiple reflective of its low margins. This could be triggered by a Q4 revenue growth deceleration or a margin miss. In this adverse scenario, the stock could realistically retest its 52-week low of $15.58, representing a -16% decline from the current $18.45 price. A more severe drawdown towards the -46.8% historical maximum is possible if the growth narrative fully unravels, though the strong balance sheet provides a floor against a total collapse.